These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 25446834

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Reduced rate of side effects associated with separate administration of MMR and DTaP-Hib-IPV vaccinations.
    Shneyer E, Strulov A, Rosenfeld Y.
    Isr Med Assoc J; 2009 Dec; 11(12):735-8. PubMed ID: 20166340
    [Abstract] [Full Text] [Related]

  • 6. Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections.
    Sørup S, Benn CS, Poulsen A, Krause TG, Aaby P, Ravn H.
    JAMA; 2014 Feb 26; 311(8):826-35. PubMed ID: 24570246
    [Abstract] [Full Text] [Related]

  • 7. Underestimating the safety benefits of a new vaccine: the impact of acellular pertussis vaccine versus whole-cell pertussis vaccine on health services utilization.
    Hawken S, Manuel DG, Deeks SL, Kwong JC, Crowcroft NS, Wilson K.
    Am J Epidemiol; 2012 Dec 01; 176(11):1035-42. PubMed ID: 23118103
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine.
    Halperin SA, Tapiéro B, Dionne M, Meekison W, Diaz-Mitoma F, Zickler P, Rubin E, Embree J, Bhuyan P, Lee A, Li M, Tomovici A.
    Pediatr Infect Dis J; 2014 Jan 01; 33(1):73-80. PubMed ID: 24346596
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety of DTaP-IPV/Hib vaccine administered routinely to infants and toddlers.
    Hansen J, Timbol J, Lewis N, Pool V, Decker MD, Greenberg DP, Klein NP.
    Vaccine; 2016 Jul 29; 34(35):4172-4179. PubMed ID: 27373595
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
    Cheng HK, Rajadurai VS, Amin Z, Sriram B, Yee MF, Han HH, Bock HL, Safary A.
    Southeast Asian J Trop Med Public Health; 2004 Sep 29; 35(3):685-92. PubMed ID: 15689088
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Safety and immunogenicity of 2 mixed primary infant immunization schedules of pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, and Haemophilus influenzae Type B vaccines at 2, 4, and 6 months of age: a randomized controlled trial.
    Langley JM, Halperin SA, Rubin E, White C, McNeil S, Mutch J, Mackinnon-Cameron D, Smith B.
    Pediatr Infect Dis J; 2012 Feb 29; 31(2):189-92. PubMed ID: 22173143
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
    Vesikari T, Forstén A, Desole MG, Ferrera G, Caubet M, Mesaros N, Boutriau D.
    Pediatr Infect Dis J; 2013 May 29; 32(5):521-9. PubMed ID: 23190785
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus Influenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China.
    Li RC, Li FX, Li YP, Hou QM, Li CG, Li YN, Chen FS, Hu XZ, Su WB, Zhang SM, Fang HH, Ye Q, Zeng TD, Liu TX, Li XB, Huang YN, Deng ML, Zhang YP, Ortiz E.
    Vaccine; 2011 Feb 24; 29(10):1913-20. PubMed ID: 21219984
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Persistence of antibodies in 4-8 year old Austrian children after vaccination with hexavalent DTaP-HBV-IPV/Hib and MMR vaccines.
    Paulke-Korinek M, Fischmeister G, Grac A, Rendi-Wagner P, Kundi M, Mohsenzadeh-Rabbani A, Moritz K, Fenninger B, Jarisch R, Jasinska J, Holzmann H, Wiedermann U, Kollaritsch H.
    Vaccine; 2011 Jul 18; 29(32):5130-6. PubMed ID: 21624412
    [Abstract] [Full Text] [Related]

  • 20. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA, Tapiero B, Diaz-Mitoma F, Law BJ, Hoffenbach A, Zappacosta PS, Radley D, McCarson BJ, Martin JC, Brackett LE, Boslego JW, Hesley TM, Bhuyan PK, Silber JL.
    Vaccine; 2009 Apr 28; 27(19):2540-7. PubMed ID: 19124057
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.